Endocrinology

A new paradigm for reducing CV morbidity and mortality provides a comprehensive approach to comorbid metabolic disease including early detection and treatment.

The phase 3 semaglutide kidney outcomes trial will be stopped immediately with FLOW read out expected in early 2024, the company said.

Your daily dose of the clinical news you may have missed.

In adults older than age 65 years with T2D, a simple clinical decision support tool plus shared decision making reduced hypoglycemic episodes by half.

Your daily dose of the clinical news you may have missed.

The addition of ileus as a potential adverse event associated with the GLP-1 mimetic is not the first required for the class by the regulator.

The prevalence of cardiac, renal, and metabolic conditions has significantly increased over 20 years and so has the number of US adults who have all 3.

Pivotal cardiovascular outcome trials that evaluated cardiorenal benefits of the newer classes were not designed to consider racial/ethnic variations, researchers state.

The biosimilar to the GLP-1 mimetic Victoza proved noninferior for reduction of HbA1c and had similar positive effects on body weight, lipids, and blood pressure.

Waist-to-hip ratio was more powerfully and consistently associated with risk of all-cause mortality than BMI or FMI, but can it replace BMI as a clinical indicator?

The new app is designed to help persons with diabetes understand how food and activity impact blood glucose levels and to revise behavior accordingly.

Overscheduled and undertrained, primary care clinicians shoulder a significant portion of the US wound care burden. Author Nima Ahmadi offers a technology-based solution.

Your daily dose of the clinical news you may have missed.

Women with PCOS and T2D in pregnancy were at greater risk for high insulin requirements, excess weight gain, and worsening of pregestation hypertension if treated with metformin.

The class of GLP-1 receptor agonists and similar agents, originally approved to treat type 2 diabetes, also reduce body weight and reduce CVD risk; what's next?

Women with an evening vs morning chronotype were 54% more likely to have unhealthy lifestyles that in turn accounted for a significant increased risk for diabetes.

The first 10 drugs identified for negotiations under the Inflation Reduction Act include several well advertised agents indicated to treat diabetes, heart failure, and other chronic diseases.

A daily dose of clinical news on Patient Care you may have missed.

Reduction in levels of 4 biomarkers was correlated with lower risk of composite cardiorenal outcomes in the CREDENCE trial, suggesting use of the panel to augment current risk assessment tools.

A daily dose of clinical news on Patient Care you may have missed.

More than 90 million adults in the US with overweight/obesity are candidates for weight loss treatment with semaglutide 2.4 mg, according to a new study.

The newly named centers across the country will work closely with communities to focus research on populations at greatest risk for perinatal morbidity and mortality.

A daily dose of clinical news on Patient Care you may have missed.

Patients with diabetes will be able to save money when ordering insulin and commonly prescribed products, such as continuous glucose monitors and pumps.

A post hoc analysis of the landmark SOLOIST-WFH trial supports avoiding delay in initiating the SGLT-2/1 inhibitor as part of guideline-recommended treatment.

A daily dose of clinical news on Patient Care you may have missed.

A daily dose of clinical news on Patient Care you may have missed.

The new policy is helping people who are taking insulin save money and helping others to afford it in the first place, says a study coauthor from the USC Sol Price School of Public Policy .

In adults with obesity or overweight plus comorbidities but without T2D once-weekly tirzepatide was associated with significant and durable weight loss vs placebo.